Charles Hewitt and Fatima Chunara had a great day on saturday mentoring and supporting the students at the Northwest Biotech Initiative Case Competition, where we were very proud to have sponsored the best speaker prize. Charles Hewitt also gave a great presentation on why he chose a career in consulting and the skills needed to thrive in the industry. #NWBICCC2018
Remap are extremely proud to be sponsoring the best speaker prize tomorrow at the Northwest Biotech Initiative Annual Consulting Case Competition. Our very own Charlie Hewitt will be talking about Strategic Consultancy within the pharmaceutical industry and how you can become a Consultant. If you are in and around Manchester tomorrow, come and join us!
How successful has the BEAM Alliance Initiative and biopharma been at addressing Antimicrobial Resistance (AMR)?
The AMR global threat Antimicrobial resistance (AMR) has long been recognised as a global epidemic but it is only relatively recently that it has been accepted by worldwide governments as a global public health crisis and an urgent threat. Today, an estimated 700,000 people die each year because of the growing number of potentially deadly infectious pathogens. These include pathogens that [...]
If you are attending the BIO 2018 International Convention in Boston, Paul Craddy and Graham Foxon would love to meet up for an informal chat to discuss any potential pricing and market access challenges you may be facing #BIO2018 #markekaccess #coffeeandconversation
Paul Craddy and Graham Foxon are at the Bio International Convention in Boston this week. If you are attending, please get in touch for an informal chat #BIO #MarketAccess #Launch #Pricing #Productvalue
Paul Craddy and Graham Foxon are looking forward to attending the #BIOConvention in Boston next week, where they will be networking with biotech and pharma companies who want to identify the potential price and value of their asset, from a payer perspective. Drop us a line if you are attending the event and wish to discuss any pricing or market access challenges you [...]
Is there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if so, are any differences are solely driven by drug costs. Read our findings here ICERS are not all the same. How [...]
We had a great few days at ISPOR Baltimore, we are now looking forward to the BIO International Convention in Boston 4-7 June. We are partnering with companies at BIO who want to identify the potential price and value of their asset, from a payer perspective. Drop us a line if you are attending and wish to discuss any market access [...]
Chris Martin from Remap Consulting will be presenting our poster at #ISPOR Baltimore on 22nd May, discussing how cost-effectiveness estimates differ between the UK and the US. Come along to our poster session between 15:30 and 19:30 (C12) for an informal chat with Chris and to learn more about what we have to offer.
ICERS ARE NOT ALL THE SAME. HOW COST-EFFECTIVENESS ESTIMATES DIFFER BETWEEN THE UK AND US OBJECTIVES: To determine if there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if any differences are [...]